Please assess the completion status of the following clinical trial:

Trial Title: Fetal Scalp Stimulation Versus Fetal Blood Sampling in Labour

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Nulliparous women~* Singleton pregnancy~* Cephalic presentation~* Gestational age 37+0 weeks or greater~* Abnormal CTG that requires second-line testing (FBS or dFSS)~Exclusion Criteria:~* Contraindication to FBS~* Limited understanding of English~* At the discretion of the responsible obstetrician in cases where there is urgency

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fetal Blood Sampling (FBS) (Type: ACTIVE_COMPARATOR): Fetal capillary blood samples will be collected in heparinised tubes and analysed in the delivery suite using the locally available gas analyser. The result of the first technically reliable sample, or the lowest reliable sample if multiple samples are tested, will be interpreted and acted upon according to the protocol, taking account of the clinical circumstances and the stage of labour:~pH ≥7.25 normal, continue and if indicated repeat in 60 minutes; pH 7.21-7.24 borderline, repeat in 30 minutes; pH ≤ 7.20 abnormal, deliver.
- digital Fetal Scalp Stimulation (dFSS) (Type: ACTIVE_COMPARATOR): The examiner will stimulate the fetal scalp digitally with the index and middle finger over a period of 30-60 seconds.The CTG will be observed over a 5-10 minutes interval after the dFSS and if a fetal heart rate acceleration (\>15 bpm for 15 seconds) is observed the test will be considered normal. If there is an episode of normal variability (5-25 bpm) but there is no clear acceleration, the test will be considered borderline. If there is no FHR acceleration and no episode of normal variability with ongoing abnormal features, the test should be interpreted as abnormal in the same way as an abnormal FBS result.~FHR acceleration normal, if indicated repeat in 60 min; Uncertain acceleration/ normal variability borderline, repeat in 30 minutes; No Acceleration/ongoing abnormal features abnormal, deliver.

Based on this trial design, predict the completion outcome and termination type (if applicable).